ABSTRACT
Colorectal cancer (CRC) is a leading contributor to morbidity and mortality worldwide (1). CRC incidence is expected to rise due to longer life expectancy and life-style changes, such as poor diet outcome among chemotherapy-treated CRC and glioblastoma patients (13-15).
Here, we performed a discovery and validation study aimed at developing stratification signatures to 74 predict personalized risk in stage III CRC (Fig. 1) . We investigated the potential of APOPTO-CELL
75
as a stand-alone tool. Moreover, we synthetized a systems-biology signature by linking APOPTO-
76
CELL with protein expression data and harnessed a machine learning approach to examine the 77 prognostic relevance of ODE-based modelling, proteomics, and clinicopathological data. We 78 validated our signatures in an independent external cohort and assessed their prognostic value for 79 distinct molecular subtypes of CRC.
Patient cohorts

84
We developed prognostic signatures for stage III colorectal cancer patients from three distinct and 85 independent collections: discovery, expansion and validation cohorts. The discovery cohort was an in-
86
house multi-center study of n=120 stage III CRC patients. The expansion dataset included n=157 
90
A detailed description of the patients data handling and inclusion criteria for downstream analyses is 91 presented in Suppl. Methods SM1.
93
Prognostic signatures
94
We developed 3 prognostic signatures: APOPTO-CELL, APOPTO-CELL-PC3 and RF. 
100
XIAP, SMAC and Procaspase-3. Previous quantitative studies found that Apaf-1 protein levels were 101 not rate-limiting for apoptosome formation in colon cancer cells (14) . Thus, Apaf-1 patient-specific 102 protein levels were replaced by the median expression (0.123 µM) previously determined in stage the APOPTO-CELL prediction for apoptosis competency in line with previous single-cell imaging pipeline illustrated in Fig. 2A .
109
First, a kernel distribution object was constructed from the normalized protein intensities ( 
155
We used the distribution of the patient-specific recurrence probabilities determined by the RF
156
classifier in the discovery cohort to define risk groups (Fig. 5E ). Survival analysis was performed classifier identification. The probability of recurrence, and thus the risk group, was computed based
Statistical Analysis
163
Kaplan-Meier estimates were used to compare disease-free (DFS) and overall survival (OS) curves 164 between groups and statistically significant differences were determined by log-rank tests. 
175
coxph and cox.zph from the package "survival" (version 2.39-2) and Anova from the package "car"
Quantitative profiling of apoptosis execution proteins in a discovery cohort of CRC patients.
patients (Fig. 1) . Suppl. 
186
We established a workflow to determine the molar concentrations required by APOPTO-CELL as
187
input from normalized RPPA data ( Fig.2A and Materials and Methods). For each protein, absolute 188 concentrations ( Fig. 2B iv) were estimated from normalized RPPA signal intensities (Fig. 2B i) via a 189 transformation function (Fig. 2B iii) determined from a reference distribution (Fig. 2B ii) . We 
214
Sensitivity analyses demonstrate high robustness of the APOPTO-CELL signature.
215
We examined whether APOPTO-CELL predictions of apoptosis susceptibility would notably change
216
when accounting for noise in the protein concentrations (Fig. 3A) . For each patient, we built a normal 217 distribution centered on the reference (unperturbed) value with a given standard deviation for each of 218 the input proteins (including Apaf-1). Next, for each patient we ran 1000 simulations with values 219 randomly drawn from these distributions (bootstrapping, (20)) and computed the predictions for 220 apoptosis competency. We then computed a robustness index (RI) as the fraction of simulations 221 matching the observed substrate cleavage (SC>25% vs. SC≤25%) in the absence of noise. We 222 investigated the RI for up to 30% variation (upper limit for intercellular heterogeneity observed in
223
( 21,22)) and defined patient-specific predictions as robust when RI≥90% (gray line in Fig. 3B comparing the robust low-vs. high-risk groups (Fig. 3D-E) . Only 16 patients (13%) were not 236 classified as low-or high-risk for at least 90% of the simulations (Fig. 3F) 
245
Apart from their defined roles in the mitochondrial apoptosis pathway, Procaspase-9, XIAP, SMAC
246
and Procaspase-3 may play roles in MOMP-and apoptosome-independent cell death pathways. They 247 may also regulate other cellular processes such as proliferation, autophagy, immune response, and 248 differentiation (23-29). As these processes could affect patient response to therapy, we examined 249 whether these proteins were independently associated with clinical outcome. Only Procaspase-3
250
(PC3) showed potential as an independent biomarker (Suppl. Fig. S1 ). We therefore included
251
Procaspase-3 levels as an additional prognostic factor in our analysis. This approach compensates for 252 apoptosome-independent Caspase-3 activation. To explore whether PC3 could further improve 253 prognostic accuracy, we combined PC3 quantifications with APOPTO-CELL model outputs
254
(APOPTO-CELL-PC3), (Fig. 4A) . We categorized patients into three groups: i) high-risk, patients 255 with low PC3 expression (≤median) and apoptosis resistance (SC≤25%); ii) low-risk, patients with patients. We observed statistically significant differences between OS and DFS curves when comparing these groups (log-rank p<0.01), (Fig. 4B-C 
266
The APOPTO-CELL-PC3 signature is an independent prognostic marker for stage III CRC 267 patients of the discovery cohort.
268
We used Cox proportional hazards regression models to examine the prognostic value of APOPTO-
269
CELL-PC3 and established clinical risk factors (Fig. 4D) 
278
We explored whether staging, primary tumor location, and lymphovascular invasion further aided in 279 patient stratification (Suppl. Fig. S2 ). We observed significant differences between OS and DFS
280
curves by lymphovascular invasion (log-rank p=0.04 for both, Suppl. Fig. S2C i-ii) , though not for 281 staging or tumor location (Suppl. Fig. S2A-B i-ii) . When stratifying by stage and location, we 282 observed significant differences between OS and DFS curves (log-rank p<0.05) by the APOPTO-lymphovascular invasion (Suppl. Fig. S2C iii) and between OS curves among patients with in the expansion cohort
290
The prognostic relevance of BRAF and MSI status has been comprehensively examined, and testing
291
of MSI status has been introduced in clinical practice (2). We used an expansion cohort (GSE39582 292 dataset, (16)) to explore whether MSI and BRAF status potentially confound associations between our 293 prognostic signatures and recurrence risk (Fig. 1) . We analyzed stage III patients with known status
294
for microsatellites and BRAF mutation (n=157), (Suppl . Table ST1 ).
295
APOPTO-CELL and APOPTO-CELL-PC3 signatures, estimated from gene expression (Suppl.
296
Methods SM2), were associated with DFS in univariate and multivariate analyses (Suppl. 
319
RF classifiers are considered 'black box' machine learning algorithms that have limited 320 interpretability. To investigate how the recurrence probability predicted by the RF classifier depended 321 on each feature and their interactions (Suppl. Fig. S3 ), we generated a synthetic cohort where each 
326
We examined how the RF features interact to deploy the final recurrence predictions. For each 327 combination of predictors, we visualized recurrence risk relative to the overall average recurrence risk
328
(the reference baseline) (Fig. 5D) . The relative risks associated with age and nodal count were 329 aggregated into three levels by averaging over all risks in the corresponding group. Suppl. Fig. S3G 330 presents this visualization without aggregation of these predictors. Overall, patients categorized as 331 low-risk by the APOPTO-CELL-PC3 signature had a reduced recurrence risk. This effect was lost in 332 advanced cancers (T4 and N2), which exhibited an overall higher probability of recurrence. Females 333 also had a higher risk of relapse than males.
curves by these groups (log-rank p<0.001), (Fig. 5F ). Patients with >50% risk had an approximately concordance index suggested that the RF signature was better at discriminating recurrence than the 340 APOPTO-CELL-PC3 signature (0.67 vs. 0.64).
342
Validation of the prognostic signatures in an independent external cohort.
343
We evaluated the prognostic value of our signatures using an independent publically available cohort:
344
TCGA COAD (Fig. 1) . Suppl. 
352
6A-C).
354
Evaluation of the prognostic value of the signatures in the context of the CRC Consensus
355
Molecular Subtypes (CMS).
356
A recent study identified four distinct consensus molecular subtypes (CMS) for CRC (30), with
357
CMS4 ('mesenchymal') vs. CMS1-3 subtypes being associated with poorer outcome. Among our 358 validation cohort, there were not differences between DFS curves by CMS4 vs. 1-3 subtypes among
359
stage III (log-rank p=0.90) or stage I-IV patients (log-rank p=0.54). Nevertheless, SC retained its but not CMS4 (Fig. 6E-F 
403
We introduced the APOPTO-CELL-PC3 signature which capitalizes on both the prognostic 
448
Emerging technologies, such as multiplexed fluorescence microscopy (MxIF, (50) magnitude of the relative risk compared to baseline whereas color indicates the direction of 685 change (red and blue for increase and decrease, respectively). 686 E. Distribution of the probability of recurrence for the patients used to develop the random 687 forest signature highlighting the cut-off thresholds employed to define risk groups. 688 F. Kaplan-Meier estimates comparing disease-free survival curves for the risk groups defined 689 by the Random Forest classifier in E. P-values were computed by log-rank tests. 690 
